Suppr超能文献

持续性非卧床腹膜透析的发病率和死亡率:区域经验与长期前景

Morbidity and mortality of continuous ambulatory peritoneal dialysis: regional experience and long-term prospects.

作者信息

Nissenson A R, Gentile D E, Soderblom R E, Oliver D F, Brax C

出版信息

Am J Kidney Dis. 1986 Mar;7(3):229-34. doi: 10.1016/s0272-6386(86)80009-9.

Abstract

The Network Coordinating Council (NCC) #4 continuous ambulatory peritoneal dialysis (CAPD) study was designed to gather basic demographic information and analyze selected outcome parameters on all patients started on CAPD in Southern California/Southern Nevada. Between early 1979 and Dec 31, 1983, 775 patients were enrolled in the study for a total experience of 878.5 patient-years. Demographic data revealed 25% of patients were over 60 years old and 17.4% were less than 20 years old at the start of CAPD, 65% were white, and 28% had chronic glomerulonephritis as a cause of end-stage renal disease (ESRD). Compared to all NCC #4 patients on dialysis (hemo and peritoneal), the young (less than 20 years old) and whites were overrepresented on CAPD. Patient outcome was assessed by life table analysis which revealed 90%, 80%, 70%, and 70% patient survival at 12, 24, 36, and 43 months, respectively; and technique success of 80%, 60%, 48%, and 40% for the same time periods, respectively. Over half of the dropout from CAPD and one third of the hospitalizations were related to recurrent infection. Few patients transferred from CAPD because of dissatisfaction with the technique or because of peritoneal membrane failure. CAPD is an excellent form of therapy for ESRD that controls uremia adequately and improves the quality of life for many patients. Long-term application of CAPD is hampered, however, by the high frequency of recurrent infections.

摘要

网络协调委员会(NCC)#4持续性非卧床腹膜透析(CAPD)研究旨在收集南加州/内华达州南部所有开始接受CAPD治疗患者的基本人口统计学信息,并分析选定的结局参数。在1979年初至1983年12月31日期间,775例患者纳入该研究,累计观察878.5患者年。人口统计学数据显示,开始接受CAPD治疗时,25%的患者年龄超过60岁,17.4%的患者年龄小于20岁,65%为白人,28%的患者因慢性肾小球肾炎导致终末期肾病(ESRD)。与所有接受透析(血液透析和腹膜透析)的NCC #4患者相比,年轻患者(小于20岁)和白人在CAPD治疗患者中占比过高。通过生命表分析评估患者结局,结果显示在12、24、36和43个月时患者生存率分别为90%、80%、70%和70%;同期技术成功率分别为80%、60%、48%和40%。超过一半的CAPD治疗中断和三分之一的住院与反复感染有关。很少有患者因对该技术不满意或腹膜功能衰竭而从CAPD治疗转出。CAPD是治疗ESRD的一种优秀疗法,能充分控制尿毒症并改善许多患者的生活质量。然而,反复感染的高发生率阻碍了CAPD的长期应用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验